Flexible, single-use systems that are decreasing capital investment and infrastructure requirements
In the biopharmaceutical industry “time to market†is a major driver. An aspect of recent technology development which has shown promise to help address this driver is the use of flexible, single-use manufacturing solutions. These solutions not only decrease or eliminate entirely the time required for production equipment preparation and cleaning, but also significantly decrease the capital investment required for construction of new production plants.
During this webinar the design of state-of-the-art bioproduction plants based on the use of single-use systems throughout the manufacturing process will be described. Particular emphasis will be placed on the flexibility and advantages of single-use systems. This will also be explained from the point of view of the contract manufacturing organisation Abzena.
The advantages of selecting a single manufacturer platform for upstream process equipment will be described, including the rationale for Abzena to select Sartorius as its partner of choice. The concept of closed processing and the affect this can have on bioproduction facility design for both recombinant proteins and highly potent conjugated products will be discussed. Overseeing all of these systems is the automation that enables modern process equipment to be operated efficiently in a controlled manner. Sartorius’ approach to automation and how it has been adopted at Abzena will also be described.
New biopharmaceutical products have great promise for improving the length and quality of people’s lives.
However, this can only be achieved through efficient design and utilisation of manufacturing plants and equipment. In this Webinar you will learn how the use of flexible, single-use systems across an integrated platform can help enable the achievement of this goal.
Register today to reserve your spot!
Presented by
Miriam Monge,
Marketing Director, Integrated Solutions, Sartorius Stedim Biotech
Miriam is best known in the industry for her contribution during the pioneering phase of single-use disposable technologies. Her current position at Sartorius Stedim Biotech focuses around building a global process development team combined with developing full bioprocess platforms based on disposable & hybrid technologies for mAbs, vaccines, ADC’s and intensified processing.
Dr. Jim Mills,
Senior Vice President, Technical Operations, Abzena
Jim has over 20 years’ experience working in the biotech and biopharmaceutical sector. He has held senior management positions at Cantab biopharmaceuticals (CEO), Xenova Biomanufacturing (Director of Operations) and Xenova Research Ltd (Leader, Upstream Process Development and Technical Business Development).
Jim has a PhD in microbial physiology and biochemistry from the University of Leicester and has published a number of papers on microbial enzymes, upstream and downstream process development.
Kevin Lynch,
Director Sales Integrated Solutions, Sartorius Stedim North America Inc
Kevin is a life sciences executive with over 25 years of experience. He has a proven track record of building high performance teams, delivering high value Sales Strategies, ensuring successful clinical process and IND, process technical transfers and GMP processing from PVRs through to BLA filing and site inspections.
He has held leadership roles for commercially licensed multi product facilities delivering over 1 Billion in revenue annually and new plant construction / renovations over 200 Million with measured success manufacturing various complex biopharmaceutical products. He has worked for top-tier US and European organizations including Shire, Genzyme, and Sartorius Stedim.
